| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEW |
therapy in rheumatoid arthritis: an update on safety
ARC Epidemiology Unit, University of Manchester, UK
Correspondence to:
Correspondence to:
Professor A J Silman
ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK; alan.Silman{at}man.ac.uk
ABSTRACT
Anti-TNF
therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.
Abbreviations: ANA, antinuclear antibody; CHF, congestive heart failure; DMARD, disease modifying antirheumatic drug; dsDNA, double stranded DNA; FDA, Federal Drug Administration; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TB, tuberculosis; TNF, tumour necrosis factor
Keywords: anti-tumour necrosis factor ; rheumatoid arthritis; safety
This article has been cited by other articles:
|
|
 |
|
  P V Voulgari, T E Markatseli, S A Exarchou, A Zioga, and A A Drosos Granuloma annulare induced by anti-tumour necrosis factor therapy Ann Rheum Dis, April 1, 2008; 67(4): 567 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dinser, M. Fousse, U. Sester, K. Albrecht, M. Singh, H. Kohler, U. Muller-Ladner, and M. Sester Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-{alpha} blocking drugs using a novel flow-cytometric interferon-{gamma} release assay Rheumatology, February 1, 2008; 47(2): 212 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF]
|
|
|
|
|
|
J. Sheppard, K. Raza, and C. D. Buckley Skin cancer in psoriatic arthritis treated with anti-TNF therapy Rheumatology, October 1, 2007; 46(10): 1622 - 1623. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kuek, B. L Hazleman, and A. J K Ostor Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution Postgrad. Med. J., April 1, 2007; 83(978): 251 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii2 - iii15. [Full Text] [PDF]
|
|
|
|
|
|
K M J Douglas, E Ladoyanni, G J Treharne, E D Hale, N Erb, and G D Kitas Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions Ann Rheum Dis, October 1, 2006; 65(10): 1341 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger The value of animal models for drug development in multiple sclerosis Brain, August 1, 2006; 129(8): 1940 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-G. Zhang, C. Liu, K. Su, S. Yu, L. Zhang, S. Zhang, J. Wang, X. Cao, W. Grizzle, and R. P. Kimberly A Membrane Form of TNF-{alpha} Presented by Exosomes Delays T Cell Activation-Induced Cell Death. J. Immunol., June 15, 2006; 176(12): 7385 - 7393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Massara, P. L. Cavazzini, and F. Trotta In SAPHO syndrome anti-TNF-{alpha} therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations Rheumatology, June 1, 2006; 45(6): 730 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv2 - iv14. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frostegard Atherosclerosis in Patients With Autoimmune Disorders Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1776 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. NAGUWA Tumor Necrosis Factor Inhibitor Therapy for Rheumatoid Arthritis Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chevillotte-Maillard, P. Ornetti, R. Mistrih, C. Sidot, J. Dupuis, J.-A. Dellas, C. Tavernier, and J. F. Maillefert Survival and safety of treatment with infliximab in the elderly population Rheumatology, May 1, 2005; 44(5): 695 - 696. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rott and U. Mrowietz Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies BMJ, March 26, 2005; 330(7493): 716 - 720. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
